Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$830M |
| 2 |
UnitedHealth
UNH
|
+$769M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$691M |
| 4 |
Amazon
AMZN
|
+$654M |
| 5 |
Bank of America
BAC
|
+$634M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 2 |
NVIDIA
NVDA
|
+$550M |
| 3 |
Spotify
SPOT
|
+$473M |
| 4 |
Citigroup
C
|
+$460M |
| 5 |
Boston Scientific
BSX
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 82.83% |
| 2 | Healthcare | 3.13% |
| 3 | Technology | 2.97% |
| 4 | Financials | 2.19% |
| 5 | Consumer Discretionary | 2.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
BGB
11076
Blackstone Strategic Credit 2027 Term Fund
BGB
$493M
| $127K | ﹤0.01% |
+10,355
| New | +$128K |
2024 Q4
0 quarters
|
|
11077
PUT
BJ's Restaurants
BJRI
$1.28B
| $126K | ﹤0.01% |
3,600
-300
| -8% | -$10.6K |
2022 Q4
8 quarters
|
|
|
AAMI
11078
CALL
Acadian Asset Management
AAMI
$3.29B
| $126K | ﹤0.01% |
4,800
-18,200
| -79% | -$510K |
2022 Q1
11 quarters
|
|
|
TEAD
11079
CALL
Teads Holding Co
TEAD
$56.8M
| $126K | ﹤0.01% |
17,600
+6,600
| +60% | +$36K |
2022 Q2
10 quarters
|
|
11080
CALL
YieldMax AMZN Option Income Strategy ETF
AMZY
$218M
| $126K | ﹤0.01% |
6,700
-10,400
| -61% | -$204K |
2024 Q2
2 quarters
|
|
|
FNA
11081
CALL
DELISTED
Paragon 28, Inc.
FNA
| $126K | ﹤0.01% |
12,200
-8,400
| -41% | -$67.8K |
2022 Q4
8 quarters
|
|
11082
CALL
Phunware
PHUN
$41.7M
| $126K | ﹤0.01% |
+24,228
| New | +$134K |
2024 Q4
0 quarters
|
|
11083
PUT
Tenaya Therapeutics
TNYA
$119M
| $126K | ﹤0.01% |
88,100
+87,700
| +21,925% | +$197K |
2024 Q1
3 quarters
|
|
11084
CALL
Hancock Whitney
HWC
$5.74B
| $126K | ﹤0.01% |
+2,300
| New | +$127K |
2024 Q4
0 quarters
|
|
11085
InflaRx
IFRX
$223M
| $126K | ﹤0.01% |
50,914
+27,973
| +122% | +$53.8K |
2023 Q3
5 quarters
|
|
11086
CALL
Ispire Technology
ISPR
$81.4M
| $126K | ﹤0.01% |
25,000
+23,100
| +1,216% | +$142K |
2023 Q4
4 quarters
|
|
11087
CALL
iShares Core MSCI Total International Stock ETF
IXUS
$58.4B
| $126K | ﹤0.01% |
1,900
-900
| -32% | -$62.5K |
2024 Q3
1 quarter
|
|
11088
TherapeuticsMD
TXMD
$23.1M
| $125K | ﹤0.01% |
+145,802
| New | +$205K |
2024 Q4
0 quarters
|
|
11089
CALL
Olema Pharmaceuticals
OLMA
$677M
| $125K | ﹤0.01% |
21,500
+15,200
| +241% | +$152K |
2023 Q2
6 quarters
|
|
|
PBT
11090
CALL
Permian Basin Royalty Trust
PBT
$1.6B
| $125K | ﹤0.01% |
11,300
-64,100
| -85% | -$768K |
2021 Q4
12 quarters
|
|
11091
CALL
Pathward Financial
CASH
$1.48B
| $125K | ﹤0.01% |
1,700
+100
| +6% | +$7.62K |
2022 Q4
8 quarters
|
|
11092
PUT
ProShares Ultra Real Estate
URE
$46.4M
| $125K | ﹤0.01% |
2,000
-100
| -5% | -$7.08K |
2022 Q4
8 quarters
|
|
|
PVLA
11093
Palvella Therapeutics
PVLA
$1.83B
| $125K | ﹤0.01% |
10,408
-1,278
| -11% | -$20.1K |
2024 Q3
1 quarter
|
|
11094
CALL
Patrick Industries
PATK
$2.09B
| $125K | ﹤0.01% |
1,500
-2,850
| -66% | -$254K |
2021 Q1
15 quarters
|
|
11095
China Yuchai International
CYD
$1.1B
| $125K | ﹤0.01% |
13,075
-23,447
| -64% | -$246K |
2024 Q3
1 quarter
|
|
11096
PUT
DLH Holdings
DLHC
$60.9M
| $124K | ﹤0.01% |
15,500
+10,000
| +182% | +$83.7K |
2022 Q4
8 quarters
|
|
11097
CALL
Perdoceo Education
PRDO
$2.04B
| $124K | ﹤0.01% |
4,700
+1,300
| +38% | +$32K |
2019 Q2
22 quarters
|
|
11098
CALL
Prime Medicine
PRME
$687M
| $124K | ﹤0.01% |
42,600
-7,500
| -15% | -$26.3K |
2023 Q3
5 quarters
|
|
11099
CALL
TFS Financial
TFSL
$4.48B
| $124K | ﹤0.01% |
9,900
+6,700
| +209% | +$89.2K |
2020 Q3
17 quarters
|
|
11100
CALL
Insteel Industries
IIIN
$567M
| $124K | ﹤0.01% |
4,600
-500
| -10% | -$14.5K |
2022 Q4
8 quarters
|
|
Similar funds
Citadel Advisors's Q4 2024 Portfolio in Review
As of Q4 2024, Citadel Advisors held 15,826 positions worth $578B, up 11% from $518B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Citadel Advisors's Q4 2024 filing shows 1,745 new, 6,427 increased, 6,082 reduced and 1,421 closed positions. Its largest new stake was Zoetis: 1,090,499 shares worth $178M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.23B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 83% a quarter earlier, followed by Healthcare and Technology.
- Citadel Advisors's largest Q4 2024 buy was Zoetis: 1,090,499 shares worth $178M.
- Citadel Advisors added most to Boeing in Q4 2024, an estimated $830M increase.
- Citadel Advisors's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.23B.
- Citadel Advisors fully exited Spotify in Q4 2024, selling an estimated $473M.
- Citadel Advisors's ten largest holdings make up 31% of its $578B portfolio in Q4 2024.
- Citadel Advisors opened 1,745 new positions and closed 1,421 in Q4 2024.
- Citadel Advisors's portfolio value rose 11% quarter-over-quarter to $578B.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.